Over 1900 Patient Derived Xenograft Models for Cancer Research

LIDE has established 1900+ high quality PDX models in almost 50 cancer types – the second largest PDX bio bank in the world.

Cancer No.  Cancer No. Cancer No.
Acute lymphoblastic leukemia 12 Extramedullary tumor 1 Multiple Myeloma 3
Acute myelocytic leukemia 16 Fallopian tube carcinoma 2 Neuroendocrine tumor 6
Adenoid cystic carcinoma (ACC) 5 Gallbladder carcinoma 36 Osteosarcoma 58
Bladder cancer 5 Gastric cancer 202 Ovarian cancer 203
Brain cancer 69 Gastrointestinal stromal tumor 6 Paget's Disease 1
Breast cancer 45 Hepatoblastoma 42 Pancreatic cancer 305
Cervical cancer 55 Hepatocellular 103 Penile cancer 2
Cholangiocarcinoma 82 Head and neck cancer 7 Periampullary carcinoma 2
Chordoma 2 Lung cancer 161 Prostate cancer 7
Chronic Lymphocytic Leukemia 2 Lymphoma 16 Rectal Cancer 81
Colon cancer 116 Malignant mesothelioma 2 Renal carcinoma 9
Duodenal carcinoma 15 Mediastinal endoblastoid sinus tumor 1 Sarcoma 38
Endometrial cancer 17 Melanoma 4 Spleen cancer 1
Esophageal cancer 42 Mucinous carcinoma 5 Urethral carcinoma 4

Table: Summary of available PDX Models

Leverage our patient derived xenograft models and partner with LIDE on your next oncology research project:

Application of PDX models in drug R&D

Fig. Schematic of oncology R&D projects available through PDX models

Search our Model Library here

Download a LIDE PDX FactSheet

 

Why LIDE Models:

  1. Many models of rare indications, drug resistant or relapsed/recurrent cancer
    Because we have a MiniPDX® testing program with hospitals all over China, LIDE has been able to amass a large collection of rare 3R (resistant, relapsed, recurrent) models for testing of potential 2nd or 3rd line treatments.
  2. Highly-specific molecular targets and hard to find genetic alterations
    LIDE has validated 200+ special drug resistant and/or genetic altered PDX models, including EGFR single/double/triple mutations in lung cancer, triple negative breast cancer, and models with KRAS mutation, HER2 amplification, or ALK/ROS1/NTRK fusion, etc.
     
    Cancer Type Resistant to Specific Genetic Alteration
    NSCLC Eriotinib
    Osimertinib
    Crizotinib
    Brigatinib
    anti PD-L1 ab    		 EGFR: exon19del/T790M/L858R/exon20ins/ C797S
    ALK: EML4-ALK/L1196M
    cMET: ampli./exon14ski/CD47-MET
    RET: KIF5B-RET
    ROS1: CD74-ROS1/G2032R
    KRAS: G12C
    PTEN: Y68X
    P13K: E726K
    Breast Cancer CDK4/6i TNBC/ER+
    Multiple Myeloma Bortezemonib CD47+/CD38+
    Cholangiocarcinoma Paclitaxel KRAS: G12C
    FGFR: BICC1-FGFR2
    Colorectal Cancer Avastin KRAS: G12C
    BRAF: V600E
    Hematological Malignancy Rituximab
    Imatinib    		 /
    Gastric Cancer Herceptin HER2: ampli
    KRAS: G12C
    Brain Cancer / EGFR: VII
    cMET: PTPRZ1-MET
    Melanoma anti PD-1 ab BRAF: V600E
    Ovarian Cancer Platinum
    PARPi    		 /
    Table: LIDE resistant and genetically modified PDX models
     
  3. Highest testing standards
    Pathological analysis will be done using H&E staining from FFPE reserved during each passage of individual PDX models by a certified pathologist under the U.S. CAP standard. WES and RNAseq will be done in most of the established models according to the highest international standards of PDX Consortium.

    Highest testing standards
     

    Download a LIDE PDX FactSheet Download a LIDE PDX and Cell Line List